Charted
Saturday, Nov. 21, 2026The business of health, by the numbers
Live trackersDeal tracker $50.9B raisedFDA clearances 293 510(k)s in OctoberForm D raises $1.5B in 30 daysNew trials 266 Phase 2/3 in 30 days
Health Tech·Danaher Corporation

Danaher enlists Microsoft to put AI agents in its lab instruments, with more due 2027

The shared platform runs on Azure and Microsoft Foundry. The first product, an assistant for Molecular Devices imaging systems, is due this year. Financial terms were not disclosed.

Charted Staff3 min read
From a company announcement published Nov. 20, 2026
The Life Sciences Complex at Syracuse University, which houses the biology, chemistry and biochemistry departments and research labs.
The Life Sciences Complex at Syracuse University, which houses the biology, chemistry and biochemistry departments and research labs. File photo.Kiran891 / Wikimedia Commons (CC BY-SA 4.0)

Danaher Corp. said Nov. 20 that it has formed a strategic partnership with Microsoft to build a shared software platform that uses AI agents to run laboratory instruments and interpret their output. The company said the first commercial product will reach its customers before the end of 2026.

Danaher said it plans more agent-enabled instruments from its businesses in 2027.

Why it matters: Danaher sells instruments through many separate operating businesses, and it described the platform as a common foundation that would let those products work together while staying open to other vendors' agents in mixed labs. The deal ties a large life sciences toolmaker's instrument software roadmap to Microsoft's cloud and agent technology. Neither company disclosed financial terms, exclusivity, or how the platform or products will be priced.

How it works

According to the announcement, the platform runs on Microsoft Azure for cloud infrastructure and on Microsoft Foundry, which supplies the AI agents that read experimental results and direct instrument control. Danaher said the design is meant to let specialized products be built on one base and reused across its technologies.

The company said the instruments are being designed to help scientists with four tasks: turning a research goal into an experiment plan, setup and methods; operating hardware within set safety limits under user oversight, including help with troubleshooting; reading results and flagging quality problems as they occur; and suggesting fixes and follow-up experiments for scientists to review.

The first product is MetaXpress Acquire AI Assistant, software from Danaher's Molecular Devices unit for its high-content cellular imaging systems. Danaher said the assistant is intended for product support. The release does not say which Danaher businesses or instruments will be part of the 2027 launches.

Danaher also cited early results from its own testing. In what the company called preliminary internal testing, novice scientists running an AI-assisted experiment on a Leica microscope needed up to 83% less time and up to 68% fewer steps than a novice without the assistant, and finished in about the time an expert would, the company said. The release does not say how many people took part, what the experiment involved, or whether anyone outside the company reviewed the results.

The backstory

Julie Sawyer Montgomery, Danaher's president and chief executive, said the goal is for the company's instruments and labs to function "as one connected Danaher." She called the partnership "an important step toward making laboratories not just connected, but intelligent."

Deb Cupp, executive vice president and chief revenue officer of Microsoft Global Enterprise, said the effort "aims to give scientists more choice and control, and more time for discovery."

Danaher presented the partnership as part of a broader strategy around AI and what it calls autonomous science. In that strategy, connected instruments come first, and experimental results would eventually help steer the next experiment, with scientists overseeing the process. The company, which says it has 60,000 employees, describes itself as a life sciences, diagnostics and biotechnology business.

The release's risk factors list uncertainty over how Danaher develops, deploys and uses artificial intelligence in its business and products. They also mention its partnerships with third parties and the debt it took on to finance its acquisition of Masimo Corporation.

What comes next

The first test is whether the Molecular Devices assistant ships by year-end as Danaher said it would. After that, investors and lab customers will be looking for the 2027 lineup: which instruments and Danaher businesses adopt the platform, and how they are priced.

The release also leaves open how the platform will work with other vendors' agents and instruments in practice. Danaher said the system will stay open to them but did not name any outside partners or technical standards.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Health Tech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.